menu
    • menu
    [{"orgOrder":0,"company":"CSL Vifor","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Acquisition","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ CSL"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Acquisition","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ CSL"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CSL Vifor \/ CARA Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ CARA Therapeutics"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Vifor \/ CARA Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ CARA Therapeutics"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Vifor \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by CSL Vifor

    Menu

    CSL Vifor

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CSL Vifor

                            Switzerland arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            CSL Vifor

                            Switzerland arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Avacopan,Rituximab

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tavneos® (avacopan) Included in Updated EULAR Recommendations for The Management Of AAV

                            Details : Tavneos (avacopan) is a complement 5a receptor (C5aR) antagonist that inhibits the interaction between C5aR and the anaphylatoxin C5a, blocking neutrophil activation and migration. Currently being developed for the treatment of ANCA-associated vasculitis...

                            Product Name : Tavneos

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 28, 2023

                            Lead Product(s) : Avacopan,Rituximab

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CSL Vifor

                            Switzerland arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            CSL Vifor

                            Switzerland arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difelikefalin

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : CARA Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kapruvia® Approved in Switzerland With Additional Regulatory Decisions Expected in H2 2022

                            Details : Kapruvia® (difelikefalin) will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients.

                            Product Name : Kapruvia

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            August 19, 2022

                            Lead Product(s) : Difelikefalin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : CARA Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CSL Vifor

                            Switzerland arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            CSL Vifor

                            Switzerland arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difelikefalin

                            Therapeutic Area : Nephrology

                            Study Phase : Approved FDF

                            Sponsor : CARA Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kapruvia® Approved by European Commission for the Treatment of Moderate-to-severe Pruritus in Hemodialysis Pa...

                            Details : Studies showed that treatment with Kapruvia® resulted in clinically meaningful improvements in pruritus severity and in pruritus-related quality of life components and was found to be generally well tolerated in patients with moderate-to-severe CKD-asso...

                            Product Name : Kapruvia

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            April 28, 2022

                            Lead Product(s) : Difelikefalin

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved FDF

                            Sponsor : CARA Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CSL Vifor

                            Switzerland arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            CSL Vifor

                            Switzerland arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : CSL

                            Deal Size : $11,700.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Finalization of Vifor Pharma Acquisition

                            Details : CSL Limited acquire Vifor Pharma's therapeutic segment of iron deficiency, nephrology and cardio-renal therapies containing Venofer® and Maltofer® and strategic growth driver Ferinject®/Injectafer® (ferric carboxymaltose).

                            Product Name : Ferinject

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : $11,700.0 million

                            February 08, 2022

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : CSL

                            Deal Size : $11,700.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CSL Vifor

                            Switzerland arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            CSL Vifor

                            Switzerland arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : CSL

                            Deal Size : $11,700.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            CSL Limited Announces Tender Offer to Acquire Vifor Pharma Ltd

                            Details : CSL Limited acquire Vifor Pharma's therapeutic segment of iron deficiency, nephrology and cardio-renal therapies containing Venofer® and Maltofer® and strategic growth driver Ferinject®/Injectafer® (ferric carboxymaltose).

                            Product Name : Ferinject

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : $11,700.0 million

                            December 14, 2021

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : CSL

                            Deal Size : $11,700.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth